Millipore Sigma Vibrant Logo

219670 CFTR Inhibitor-172 - CAS 307510-92-5 - Calbiochem

CFTR Inhibitor-172, CAS 307510-92-5, is a cell-permeable, potent, reversible, rapid, and voltage-independent inhibitor of CFTR-mediated Cl- transport in human airway cells (Ki ~ 300 nM).

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: 3-[(3-Trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone, CFTRinh-172

Primary Target: CFTR
View Products on Sigmaaldrich.com
219670
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
307510-92-5C₁₈H₁₀F₃NO₃S₂

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
219670-5MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA cell-permeable 2-thio-4-thiazolidinone compound that acts as a potent, reversible, rapid, and voltage-independent inhibitor of CFTR (cystic fibrosis transmembrane conductance regulator)-mediated Cl- transport in human airway cells (Ki ~ 300 nM). It does not prevent elevation of cellular cAMP, nor does it inhibit non-CFTR Cl- channels, MDR-1, ATP-sensitive K+ channels, or a series of other transporters even at concentrations as high as 5 µM. Shown to block cholera toxin-induced intestinal fluid secretion in mice. May be also useful for reducing intestinal fluid loss in other secretory diarrheas. Also available as a 50 mM solution in DMSO (Cat. No. 219674).
      Catalogue Number219670
      Brand Family Calbiochem®
      Synonyms3-[(3-Trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone, CFTRinh-172
      References
      ReferencesYang, H., et al. 2003. J. Biol. Chem. 278, 35079.
      Al-Awqati, Q., et al. 2002. J. Clin. Invest. 110, 1599.
      Ma, T., et al. 2002. J. Clin. Invest. 110, 1651.
      Product Information
      CAS number307510-92-5
      ATP CompetitiveN
      FormYellow solid
      Hill FormulaC₁₈H₁₀F₃NO₃S₂
      Chemical formulaC₁₈H₁₀F₃NO₃S₂
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetCFTR
      Primary Target K<sub>i</sub>~ 300 nM against CFTR (cystic fibrosis transmembrane conductance regulator)-mediated Cl- transport in human airway cells
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      219670-5MG 04055977201550

      Documentation

      CFTR Inhibitor-172 - CAS 307510-92-5 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      CFTR Inhibitor-172 - CAS 307510-92-5 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      219670

      Références bibliographiques

      Aperçu de la référence bibliographique
      Yang, H., et al. 2003. J. Biol. Chem. 278, 35079.
      Al-Awqati, Q., et al. 2002. J. Clin. Invest. 110, 1599.
      Ma, T., et al. 2002. J. Clin. Invest. 110, 1651.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-April-2011 RFH
      Synonyms3-[(3-Trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone, CFTRinh-172
      DescriptionA cell-permeable 2-thio-4-thiazolidinone compound that acts as a potent, reversible, rapid, and voltage-independent inhibitor of CFTR (cystic fibrosis transmembrane conductance regulator)-mediated Cl- transport in human airway cells (Ki ~ 300 nM). It does not prevent elevation of cellular cAMP, nor does it inhibit non-CFTR Cl- channels, MDR-1, ATP-sensitive K+ channels, or a series of other transporters even at concentrations as high as 5 µM. Shown to block cholera toxin-induced intestinal fluid secretion in mice. May be also useful for reducing intestinal fluid loss in other secretory diarrheas.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number307510-92-5
      Chemical formulaC₁₈H₁₀F₃NO₃S₂
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesYang, H., et al. 2003. J. Biol. Chem. 278, 35079.
      Al-Awqati, Q., et al. 2002. J. Clin. Invest. 110, 1599.
      Ma, T., et al. 2002. J. Clin. Invest. 110, 1651.